Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene

Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene

    Kevin Cook headshot

    5 Healthcare Innovators I'm Still Buying

    When you think long-term about the megatrends in healthcare, it makes picking winners easier

      Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View

      Alexion Pharmaceuticals, Inc.'s (ALXN) first-quarter 2017 earnings (including stock-based compensation expense) of $1.20 per share compared with the year ago earnings of 76 cents. The reported figure surpassed the Zacks Consensus Estimate of $1.05.

        Alexion (ALXN) Tops Q1 Earnings, Sales; Shares Up

        Alexion surpassed earnings and sales expectations in the first quarter of 2017.

          Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?

          Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.

            Arpita Dutt headshot

            Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed

            Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.

              Arpita Dutt headshot

              Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study

              Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.

                Alexion (ALXN) Files for Soliris' Label Expansion in Japan

                Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).

                  Alexion (ALXN) Licenses Artubus Technology for Rare Diseases

                  Alexion Pharmaceuticals, Inc. (ALXN) has recently licensed Arbutus Biopharma proprietary LNP technology for use in rare disease programs.

                    Alexion's sBLA for Soliris Receives FDA Acknowledgement

                    Alexion Pharmaceuticals, Inc. (ALXN) announced that the FDA, on Mar 9, has accepted the supplemental Biologics License Application (sBLA) to expand the indication for Soliris

                      Arpita Dutt headshot

                      Is This the Right Time to Invest in Biotech Stocks?

                      The biotech sector rebounded in 2017 and is on a roll since the beginning of the year -- will the rally continue?

                        Drug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More

                        With the curtains almost down on the Q4 earnings season, we believe this quarter has turned out to be a good one with growth on track to be the highest in the last two years.

                          Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More

                          The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.

                            Arpita Dutt headshot

                            Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

                            While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.

                              Arpita Dutt headshot

                              Forget Alexion, Buy these 4 Biotech Stocks Instead

                              We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

                                Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS

                                Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.

                                  Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y

                                  Alexion Pharmaceuticals, Inc.'s (ALXN) fourth-quarter 2016 earnings (including stock-based compensation expense) of $1.10 cents per share compared with the year ago earnings of 78 cents.

                                    Alexion (ALXN) Misses on Q4 Earnings and Revenues

                                    Alexion missed on earnings expectations in the fourth quarter of 2016.

                                      Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More

                                      The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.

                                        Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?

                                        Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.

                                          4 Top Biotech Mutual Funds for 2017

                                          Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance

                                            Arpita Dutt headshot

                                            Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again

                                            Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.

                                              Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU

                                              Alexion (ALXN) has filed regulatory applications in both the U.S. and EU for Soliris for the treatment of patients with refractory generalized myasthenia gravis.

                                                Alexion Blood Disorder Drug Gets Orphan Designation in U.S.

                                                Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

                                                  Company News for January 06, 2017

                                                  Companies In The News are: ALXN,CEB,IT,SHLD,SWK,HALO